Top Stories
Since its first mission launched in 2023, Varda has completed six reentry missions with over a dozen more launches and reentries planned through 2028.
The company said tulisokibart, designed to help address immuno-fibrosis, posted up to a 72% HiSCR50 response at week 16 in Phase II testing.
Roche and Zealand's amylin analogue showed weight loss peaked at the 5-mg dose, where patients achieved a 9.8% reduction.
The real-world data showed that people who switched from injectable GLP-1 based therapies to oral Wegovy (semaglutide) lost an average of 4.1% of their body weight in three months
Beam alleges YOLT-202 was copied from BEAM-302 after researcher Zi Jun Wang allegedly accessed confidential data before leaving the company.
Conference News
-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 ---- Robust durability, including maintenance and deepening of response, observed following the 16-wee...
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or complete...
The presentation will showcase advancements in the development of BIO 300 (BYOGRAYZ™) Injectable Suspension, an investigational prophylactic Medical Countermeasure (MCM) being developed to prevent rad...
HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announ...
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 y...
